ARCH:CA:CDX-Arch Biopartners Inc. (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 2.2

Change

-0.17 (-7.17)%

Market Cap

USD 0.02B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Arch Biopartners Inc is a biotechnology company. The Companis engaged in development of technologies that have the potential to make a medical or commercial impact. Its portfolio includes AB569, MetaMx, MetaBlok, Borg, and Arch Inflammation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.16B
MIR:CA MedMira Inc

N/A

USD 0.05B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.03B
CZO:CA Ceapro

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

N/A

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing ARCH:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 48.65% 81% B- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.65% 81% B- 86% B+
Trailing 12 Months  
Capital Gain 0.46% 70% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.46% 70% C- 76% C+
Trailing 5 Years  
Capital Gain 80.33% 81% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.33% 81% B- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 32.82% 88% B+ 77% C+
Dividend Return 32.82% 88% B+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.22% 21% F 33% F
Risk Adjusted Return 41.96% 92% A 85% B
Market Capitalization 0.02B 96% N/A 95% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.